Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lomitapide for the management of homozygous familial hypercholesterolemia.

Reviews in cardiovascular medicine - 1 Jan 2014

deGoma Emil M

Abstract excerpt

Homozygous familial hypercholesterolemia (HoFH) is a rare genetic disorder of low-density lipoprotein cholesterol (LDL-C) metabolism resulting in extremely elevated serum levels of LDL-C and premature atherosclerotic cardiovascular disease. Treatment typically involves multiple pharmacologic agents, as well as mechanical filtration using weekly or biweekly LDL apheresis. Despite combination lipid-lowering...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticholesteremic Agents
Share to Benzimidazoles
Share to Cardiovascular Diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carrier Proteins

Share to Cholesterol, LDL

Share to Drug Interactions

Share to Homozygote

Share to Hyperlipoproteinemia Type II

Source

Identifiers

PMID: 25051128
DOI: 10.3909/ricm0735

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lomitapide for the management of homozygous familial hypercholesterolemia.PMID 25051128Read ↗

Lomitapide for the treatment of hypercholesterolemia.Semantic proximity Read ↗

Use of microsomal triglyceride transfer protein inhibitors in patients with homozygous familial hypercholesterolemia: translating clinical trial experience into clinical practice.Semantic proximity Read ↗

The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - a post-hoc analysis of a Phase 3, single-arm, open-label trial.Semantic proximity Read ↗

Balancing Low-density Lipoprotein Cholesterol Reduction and Hepatotoxicity With Lomitapide Mesylate and Mipomersen in Patients With Homozygous Familial Hypercholesterolemia.Semantic proximity Read ↗

Management of homozygous familial hypercholesterolaemia in two brothers.Semantic proximity Read ↗

Inhibition of hepatic microsomal triglyceride transfer protein - a novel therapeutic option for treatment of homozygous familial hypercholesterolemia.Semantic proximity Read ↗

Microsomal transfer protein (MTP) inhibition-a novel approach to the treatment of homozygous hypercholesterolemia.Semantic proximity Read ↗

MTTP gene variants and lomitapide response in a cohort of patients with homozygous familial hypercholesterolemiaSemantic proximity Read ↗

MTP Gene Variants and Response to Lomitapide in Patients with Homozygous Familial Hypercholesterolemia.Semantic proximity Read ↗

Mipomersen and lomitapide: Two new drugs for the treatment of homozygous familial hypercholesterolemia.Semantic proximity Read ↗

Individual analysis of patients with HoFH participating in a phase 3 trial with lomitapide: The Italian cohort.Semantic proximity Read ↗

Autosomal recessive hypercholesterolemia: update for 2020.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.